Original Article
Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer
Table 2
Details of FOLFOX therapy.
| | Group A () | Group B () | Group C () | Group D () | Total () |
| | FOLFOX | | | | | | | FOLFOX4 | 4 | 0 | 0 | 33 | 37 | | mFOLFOX6 | 7 | 14 | 21 | 11 | 53 | | Cumulative oxaliplatin Dose (mg ) | | | | | | | Median | 807.5 | 500.0 | 750.0 | 680.0 | 680.0 | | Mean | 726.3 | 534.3 | 686.7 | 625.0 | 632.3 | | Range | 300–850 | 170–850 | 180–850 | 235–850 | 170–850 | | Total oxaliplatin dose 500 mg | 90.9% | 42.9% | 90.5% | 81.8% | 78.9% | | Percentage of patients | () | () | () | () | () | | in group | | | | | | | No. of courses | | | | | | | Median | 10.0 | 6.0 | 10.0 | 8.0 | 8.5 | | Mean | 8.9 | 6.8 | 8.8 | 7.9 | 8.0 | | Range | 4–10 | 2–10 | 3–10 | 3–10 | 2–10 |
|
|
Group A, GJG; Group B, Ca/Mg; Group C, GJG + Ca/Mg; Group D, no therapy.
GJG, goshajinkigan; Ca, calcium gluconate; Mg, magnesium sulfate.
|
